Document is current

Article History

Received: 7 November 2023

Accepted: 2 April 2024

First Online: 10 April 2024

Declarations

:

: This study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonization (ICH) Good Clinical Practice (GCP). The local Ethics Committee reviewed and approved the study protocol. Each patient provided written informed consent prior to the study procedure. Ethics committees at all participating institutions reviewed and approved this study namely - Ethics committees of Shanghai East Hospital, School of Medicine, Tongji University, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, the Sixth Affiliated Hospital of Sun Yat-Sen University, Harbin Medical University Cancer Hospital and the First Affiliated Hospital of Bengbu Medical College (Online Supplementary Table SInternalRef removed).

: Not applicable.

: Yu Wang, Haige Shen, Huaqiang Zhu, Dong Liu, Jing Wang, Shuang Wang, Congqiao Zhao, Yue Zhang report being an employee of GenFleet Therapeutics Inc., Shanghai. Jin Li reports honoraria from Roche, Merck Sharp & Dohme, AstraZeneca and Boehringer Ingelheim. Yu Wang reports stock ownership in Abbisko Therapeutics and Laekna Therapeutics. Haige Shen reports stock ownership in Laekna Therapeutics. Other co-authors declare no competing interests.